Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity

PLoS Genetics

Volumn 8, Issue 6, 2012, Pages

  Callegari, Sylvie ^a   Gregory, Philip A ^b,c   Sykes, Matthew J ^a   Bellon, Jennifer ^d   Andrews, Stuart ^a   McKinnon, Ross A ^e   de Barros Lopes, Miguel A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d AUSTRALIAN WINE RESEARCH INSTITUTE   (United States)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ELONGATION FACTOR 2; GALACTOSE; MYOCYTE ENHANCER FACTOR 2; ELONGATION FACTOR; ELONGATION FACTOR G; HEPTANOIC ACID DERIVATIVE; MEF2 PROTEIN, S CEREVISIAE; PYRROLE DERIVATIVE; SACCHAROMYCES CEREVISIAE PROTEIN; SMALL INTERFERING RNA;

AEROBIC METABOLISM; AMINO ACID ANALYSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL RESPIRATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG SENSITIVITY; ELONGATION FACTOR 2 GENE; FUNGAL GENE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MEF2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; CELL LINE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; PHYSIOLOGY; RIBOSOME; SACCHAROMYCES CEREVISIAE;

CELL DEATH; CELL LINE; CELL RESPIRATION; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; MITOCHONDRIA; PEPTIDE ELONGATION FACTOR G; PEPTIDE ELONGATION FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RIBOSOMES; RNA, SMALL INTERFERING; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84864050006     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002755     Document Type: Article

References (58)

1. Coenen MJ, Antonicka H, Ugalde C, Sasarman F, Rossi R, (2004) Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N Engl J Med 351: 2080 2086.
2. Antonicka H, Sasarman F, Kennaway NG, Shoubridge EA, (2006) The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1. Hum Mol Genet 15: 1835 1846.
3. Valente L, Tiranti V, Marsano RM, Malfatti E, Fernandez-Vizarra E, (2007) Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am J Hum Genet 80: 44 58.
4. Antonicka H, Ostergaard E, Sasarman F, Weraarpachai W, Wibrand F, (2010) Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am J Hum Genet 87: 115 122.
5. Vladutiu G, Simmons Z, Isackson P, Tarnopolsky M, Peltier W, (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 32: 153 162.
6. Baruffini E, Lodi T, (2010) Construction and validation of a yeast model system for studying in vivo the susceptibility to nucleoside analogues of DNA polymerase gamma allelic variants. Mitochondrion 10: 183 187.
7. De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc J, (1996) Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42: 333 337.
8. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, (2008) Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 26: 343 351.
9. Vladutiu G, (2008) Genetic predisposition to statin myopathy. Curr Opin Rheumatol 20: 648 655.
10. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ, (2008) Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23: 1182 1186.
11. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137: 581 585.
12. Tay S, DiMauro S, Pang A, Lai P, Yap H, (2008) Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol 39: 426 428.
13. Chariot P, Abadia R, Agnus D, Danan C, Gherardi RK, (1993) Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 94: 109 110.
14. Thomas JE, Lee N, Thompson P, (2007) Statins provoking MELAS syndrome. A case report. Eur Neurol 57: 232 235.
15. Rinaldi T, Dallabona C, Ferrero I, Frontali L, Bolotin-Fukuhara M, (2010) Mitochondrial diseases and the role of the yeast models. FEMS Yeast Res 10: 1006 1022.
16. Barrientos A, (2003) Yeast models of human mitochondrial diseases. IUBMB Life 55: 83 95.
17. Schwimmer C, Rak M, Lefebvre-Legendre L, Duvezin-Caubet S, Plane G, (2006) Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening. Biotechnol J 1: 270 281.
18. Callegari S, McKinnon RA, Andrews S, de Barros Lopes MA, (2010) Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation. FEMS Yeast Res 10: 188 198.
19. Macreadie IG, Johnson G, Schlosser T, Macreadie PI, (2006) Growth inhibition of Candida species and Aspergillus fumigatus. FEMS Microbiol Lett 262: 9 13.
20. Fowler DM, Cooper SJ, Stephany JJ, Hendon N, Nelson S, (2011) Suppression of statin effectiveness by copper and zinc in yeast and human cells. Mol Biosyst 7: 533 544.
21. Towpik J, (2005) Regulation of mitochondrial translation in yeast. Cell Mol Biol Lett 10: 571 594.
22. Smits P, Smeitink J, van den Heuvel L, (2010) Mitochondrial translation and beyond: Processes implicated in combined oxidative phosphorylation deficiencies. J Biomed Biotechnol 2010: 1 24.
23. Tsuboi M, Morita H, Nozaki Y, Akama K, Ueda T, (2009) Ef-G2mt is an exclusive recycling factor in mammalian mitochondrial protein synthesis. Mol Cell 35: 502 510.
24. Hammarsund M, Wilson W, Corcoran M, Merup M, Einhorn S, (2001) Identification and characterisation of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution. Hum Genet 109: 542 550.
25. Gao N, Zavialov AV, Ehrenberg M, Frank J, (2007) Specific interaction between EF-G and RRF and its implication for GTP-dependent ribosome splitting into subunits. J Mol Biol 374: 1345 1358.
26. Christian B, Haque E, Spremulli L, (2009) Ribosome shifting or splitting: it is all up to the EF-G. Mol Cell 35: 400 402.
27. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A 101: 793 798.
28. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121 137.
29. Hillenmeyer ME, Ericson E, Davis RW, Nislow C, Koller D, (2010) Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action. Genome Biol 11: 1 17.
30. Callegari S, McKinnon RA, Andrews S, de Barros Lopes MA, (2011) The MEF2 gene is essential for yeast longevity, with a dual role in cell respiration and maintenance of mitochondrial membrane potential. FEBS Lett 585: 1140 1146.
31. Vergani L, Prescott AR, Holt IJ, (2000) Rhabdomyosarcoma ρ0 cells: isolation and characterization of a mitochondrial DNA depleted cell line with 'muscle-like' properties. Neuromuscul Disord 10: 454 459.
32. Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, (2003) Comparing myotoxic effects of squalene synthase inhibitor T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 66: 2133 2139.
33. Araki M, Motojima K, (2008) Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells. Biochem Biophys Res Commun 367: 462 467.
34. Rorbach J, Richter R, Wessels HJ, Wydro M, Pekalski M, (2008) The human mitochondrial ribosome recycling factor is essential for cell viability. Nucleic Acids Res 36: 5787 5799.
35. Wittmann C, Kim HM, John G, Heinzle E, (2003) Characterization and application of an optical sensor for quantification of dissolved O2 in shake-flasks. Biotechnol Lett 25: 377 380.
36. Rodríguez-Enríquez S, Juárez O, Rodríguez-Zavala JS, Moreno-Sánchez R, (2001) Multisite control of the Crabtree effect in ascites hepatoma cells. Eur J Biochem 268: 2512 2519.
37. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y, (2007) Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97: 539 547.
38. Taylor SD, Zhang H, Eaton JS, Rodeheffer MS, Lebedeva MA, (2005) The conserved Mec1/Rad53 nuclear checkpoint pathway regulates mitochondrial DNA copy number in Saccharomyces cerevisiae. Mol Biol Cell 16: 3010 3018.
39. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, (2006) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63: 2415 2425.
40. Liu Z, Butow RA, (2006) Mitochondrial retrograde signaling. Annu Rev Genet 40: 159 185.
41. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, (2009) Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 4: 1 13.
42. Hansson S, Singh R, Gudkov AT, Liljas A, Logan DT, (2005) Crystal structure of a mutant elongation factor G trapped with a GTP analogue. FEBS Lett 579: 4492 4497.
43. Kaiser J, (2008) DNA sequencing: a plan to capture human diversity in 1000 genomes. Science 319: 395.
44. King MP, Attardi G, (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500 503.
45. Reitzer LJ, Wice BM, Kennell D, (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669 2676.
46. Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, (2005) Simvastatin induces impairement in skeletal muscle while heart is protected. Biochem Biophys Res Commun 338: 1426 1434.
47. Sirvent P, Mercier J, Vassort G, Lacampagne A, (2005) Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 329: 1067 1075.
48. Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud de Mauverger E, (2012) Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 259: 263 268.
49. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA, (2007) Genetic determinants of statin intolerance. Lipids Health Dis 6: 1 5.
50. Chong P, Seeger JD, Franklin C, (2001) Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 111: 390 400.
51. Schick BA, Laaksonen R, Frohlich JJ, Lehtimaki T, Humphries KH, (2007) Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 81: 650 653.
52. Bergman M, Salman H, Djaldetti M, Alexandrova S, Punsky I, (2003) Ultrastructure of mouse striated muscle fibers following pravastatin administration. J Muscle Res Cell Motil 24: 417 420.
53. Westwood FR, Scott RC, Marsden AM, Bigley A, Randall K, (2008) Rosuvastatin: Characterization of induced myopathy in the rat. Toxicol Pathol 36: 345 352.
54. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901 906.
55. Storici F, Durham CL, Gordenin DA, Resnick MA, (2003) Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast. Proc Natl Acad Sci U S A 100: 14994 14999.
56. Melo F, Feytmans E, (1998) Assessing protein structures with a non-local atomic interaction energy. J Mol Biol 277: 1141 1152.
57. Laskowski RA, MacArthur MW, Moss D, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283 291.
58. Huang X, Miller W, (1991) A time-efficient, linear-space local similarity algorithm. Adv Appl Math 12: 337 357.